Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 685

1.

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.

Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA.

J Virol. 2004 Oct;78(20):11198-207.

3.

Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.

Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S.

J Virol. 2016 Oct 14;90(21):10022-10038. Print 2016 Nov 1.

6.

Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.

Liang B, Munir S, Amaro-Carambot E, Surman S, Mackow N, Yang L, Buchholz UJ, Collins PL, Schaap-Nutt A.

J Virol. 2014 Apr;88(8):4237-50. doi: 10.1128/JVI.03481-13. Epub 2014 Jan 29.

7.

A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Wang D, Phan S, DiStefano DJ, Citron MP, Callahan CL, Indrawati L, Dubey SA, Heidecker GJ, Govindarajan D, Liang X, He B, Espeseth AS.

J Virol. 2017 May 12;91(11). pii: e00066-17. doi: 10.1128/JVI.00066-17. Print 2017 Jun 1.

8.

Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, Yang L, McLellan JS, Graham BS, Kwong PD, Schaap-Nutt A, Collins PL, Munir S.

J Virol. 2015 Sep;89(18):9499-510. doi: 10.1128/JVI.01373-15. Epub 2015 Jul 8.

9.

Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.

Phan SI, Zengel JR, Wei H, Li Z, Wang D, He B.

J Virol. 2017 Sep 12;91(19). pii: e00560-17. doi: 10.1128/JVI.00560-17. Print 2017 Oct 1.

PMID:
28747496
10.

A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.

Tang RS, Mahmood K, Macphail M, Guzzetta JM, Haller AA, Liu H, Kaur J, Lawlor HA, Stillman EA, Schickli JH, Fouchier RA, Osterhaus AD, Spaete RR.

Vaccine. 2005 Feb 25;23(14):1657-67.

PMID:
15705469
11.

Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.

Liu X, Liang B, Ngwuta J, Liu X, Surman S, Lingemann M, Kwong PD, Graham BS, Collins PL, Munir S.

J Virol. 2017 Oct 27;91(22). pii: e01101-17. doi: 10.1128/JVI.01101-17. Print 2017 Nov 15.

PMID:
28835504
12.

A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.

Wiegand MA, Gori-Savellini G, Gandolfo C, Papa G, Kaufmann C, Felder E, Ginori A, Disanto MG, Spina D, Cusi MG.

J Virol. 2017 Apr 28;91(10). pii: e02298-16. doi: 10.1128/JVI.02298-16. Print 2017 May 15.

13.

Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.

Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, Liu X, Yang L, Herbert R, Swerczek J, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Collins PL, Munir S.

J Virol. 2017 Jul 12;91(15). pii: e00189-17. doi: 10.1128/JVI.00189-17. Print 2017 Aug 1.

PMID:
28539444
14.

Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.

Tang RS, Schickli JH, MacPhail M, Fernandes F, Bicha L, Spaete J, Fouchier RA, Osterhaus AD, Spaete R, Haller AA.

J Virol. 2003 Oct;77(20):10819-28.

15.
17.

A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.

Rostad CA, Stobart CC, Gilbert BE, Pickles RJ, Hotard AL, Meng J, Blanco JC, Moin SM, Graham BS, Piedra PA, Moore ML.

J Virol. 2016 Jul 27;90(16):7508-18. doi: 10.1128/JVI.00012-16. Print 2016 Aug 15.

19.

Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector.

Wiegand M, Gori-Savellini G, Martorelli B, Bossow S, Neubert WJ, Cusi MG.

Vaccine. 2013 Aug 20;31(37):3888-93. doi: 10.1016/j.vaccine.2013.06.053. Epub 2013 Jul 2.

PMID:
23831325
20.

Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.

Piedra PA, Glezen WP, Kasel JA, Welliver RC, Jewel AM, Rayford Y, Hogerman DA, Hildreth SW, Paradiso PR.

Vaccine. 1995 Aug;13(12):1095-101.

PMID:
7491817

Supplemental Content

Support Center